Exelixis, Inc.
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Drugs in Pipeline
12
Phase 3 Programs
10
Upcoming Catalysts
2
Next Catalyst
May 15, 2026
8dMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
Regorafenib Phase 3 Results Expected
Primary completion for Regorafenib trial (NCT05425940) in Colorectal Cancer
SourceXL092 Phase 3 Results Expected
Primary completion for XL092 trial (NCT05425940) in Colorectal Cancer
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Cabozantinib
Solid Tumors
prednisone
Prostate Cancer
Everolimus
Pancreatic Neuroendocrine Tumor (pNET)
Cabozantinib tablets
Renal Cell Carcinoma
Abiraterone Acetate
Metastatic Prostate Cancer
XL092
Non-Clear Cell Renal Cell Carcinoma
XL184
Glioblastoma Multiforme
Sorafenib
Hepatocellular Carcinoma
Regorafenib
Colorectal Cancer
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
erlotinib
Carcinoma, Non-Small-Cell Lung
XL820
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cabozantinib | Phase 3 | Solid Tumors | - | - |
prednisone | Phase 3 | Prostate Cancer | - | - |
Everolimus | Phase 3 | Pancreatic Neuroendocrine Tumor (pNET) | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
Abiraterone Acetate | Phase 3 | Metastatic Prostate Cancer | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |